Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclidinium bromide versus placebo and tiotropium in stable moderate to severe COPD
2008-006886-10Phase 2Completed
- Sponsor
- Almirall
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of aclidinium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Almirall. Primary endpoint: Efficacy of inhaled aclidinium bromide 400 micrograms twice daily. Started Dec 2008; status: completed.
02
Drugs
aclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-006886-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006886-10.